Pharmacy can help shape the NHS of the future - if we let it

As the NHS moves towards a new model of care, is community pharmacy still searching for its place within it?

Dr Ruth Miller

Across the four nations of the UK, healthcare policy is increasingly focused on delivering more integrated, preventative care closer to home. Neighbourhood-based models are gaining momentum, though still at an early stage, and community pharmacy has considerable potential to contribute.

But before designing new services, expanding clinical roles or establishing integrated teams, perhaps we should ask a more fundamental question.

What problem are we actually trying to solve?

It sounds obvious, yet healthcare can become preoccupied with solutions before fully understanding the problems they are intended to address. Integration is not an outcome but a mechanism through which better outcomes might be achieved.

Establishing multidisciplinary teams or moving care into community settings does not guarantee better patient care or more sustainable services. Successful healthcare redesign must be defined by what changes for patients, populations and the wider system.

Over a career that began in community pharmacy and has spanned every sector, I have often examined healthcare policy and strategy documents, searching for references to pharmacy and identifying opportunities to align gaps in pharmacy services with established priorities.

Read more: ‘Fund and empower’ pharmacies to fight health inequality, bodies urge

Early signs suggest pharmacy is not yet embedded in many local plans. That exercise is important, but it increasingly prompts another question: why are we so often looking for opportunities within strategies already developed, rather than helping shape them from the outset?

Community pharmacy brings accessibility, clinical expertise, knowledge of local populations and an understanding of medicines-related risks and expenditure. These perspectives should inform decisions about how healthcare services are designed, funded and evaluated. However, representation alone is not enough. Meaningful involvement requires the opportunity to influence decisions before solutions have been determined.

Read more: National strategy launched to boost research in pharmacy

The expansion of pharmacist independent prescribing illustrates both the opportunities and challenges ahead. Prescribing offers considerable potential to enhance clinical care and further strengthen community pharmacy as a career destination.

But developing prescribing capability is not the same as creating the conditions in which it can be used effectively. Community pharmacies are already balancing substantial dispensing, clinical and operational responsibilities. Expanding their role requires more than additional service specifications and professional goodwill.

Value and viability

Workforce availability, skill mix, protected clinical time, supervision, digital infrastructure, governance and the continuing delivery of existing services must be considered as foundational. Crucially, funding must reflect the true cost of providing care, not simply the volume of consultations delivered.

Transferring activity from general practice or hospitals into community pharmacy does not automatically create additional capacity or reduce overall costs. Without adequate investment, even clinically valuable services can become operationally and financially unsustainable.

Read more: RCPharm urges government to use pharmacists to tackle corridor care

There is also a challenge for the whole profession. We have long advocated the clinical and economic contribution we can make. Yet we have not always had the capacity or support to generate the evidence consistently. Within integrated neighbourhood pathways, outcomes may be achieved collectively across several professions. Nevertheless, pharmacy must demonstrate its contribution, the resources required and the value it adds.

Clinical outcomes, patient experience, economic impact and return on investment must be considered from the outset. Evaluation should be built in, not added when funding is questioned. We must distinguish between value for the wider healthcare system and financial viability for individual pharmacies.

A service that reduces hospital activity but is inadequately resourced at the point of delivery is unlikely to represent a sustainable model. Return on investment should not be reduced to financial savings alone; the economic case must weigh patient outcomes alongside the full costs of safe delivery.

Read more: Pharmacy bodies, minister discuss ‘failures’ in primary care access

There is another dimension to sustainable service development that deserves equal attention: strategic and political alignment. Healthcare services do not exist in isolation. Their future is influenced by national policy, organisational priorities, commissioning decisions and competition for limited resources.

This alignment is a lens to apply throughout service design and delivery, not only when seeking funding. Even a well-designed, evidence-based service can struggle to survive if its contribution to organisational priorities is poorly understood. Conversely, strategic alignment alone cannot rescue a service lacking sound design or demonstrable value.

Both are essential, although neither guarantees investment when resources are constrained.

An opportunity we must design for

Neighbourhood healthcare offers community pharmacy a significant opportunity, but ambition must extend beyond securing additional services or responsibilities. We should ask where our expertise can make the greatest difference, how that contribution will be demonstrated and what resources are needed to sustain it.

Community pharmacy’s future should not be defined simply by what more it can do, but by the problems it can help healthcare systems solve and the evidence that demonstrates its value.

That is how we move from trying to find our place in healthcare strategy to helping shape services capable of delivering outcomes that last.

Dr Ruth Miller is lead research pharmacist at the Western HSC Trust, seconded to the Northern Ireland Centre for Pharmacy Learning and Development as senior foundation trainee pharmacist selection and admissions lead.

She is also founder of EFRM Consulting Ltd and author of “Build. Transform. Last”.

Latest from Opinion

More from Analysis